Cocrystal Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on May 11, 2022. The filing serves to announce the Company's results of operations for the fiscal quarter ended March 31, 2022. The Company's common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
This Form 8-K is a notification of results and does not contain specific financial data points within the text provided. The filing references a press release (Exhibit 99.1) for detailed figures. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document. The filing text does not provide a clear value for these metrics.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely indicates that results for the quarter ended March 31, 2022, have been issued via a press release.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. It explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 11, 2022) for actual revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the referenced press release.
- Confirm the status of the Co-Interim Chief Executive Officer role held by James Martin.
- Check for any subsequent filings that may incorporate the press release by reference.